Why the study?
TRPM4 is linked to human cardiac diseases, and the human mutation K914R was identified in patients with atrioventricular block.
Design
Preclinical mutagenesis and molecular modeling study
Authors
Loading...
Animal data suggest TRPM4 interface modulation as a potential conduction disease target; human translation remains untested.
The K914R mutation in TRPM4 causes a gain-of-function in cardiac conduction disease that can be offset by modulating the nanoscopic interface, suggesting a novel therapeutic target.
Xian et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: